News

RSV vaccine recommended during pregnancy as a second option to protect newborns | AP News

Regulatory 50/100How we got 50/100Source tierUnclassified sourceTier ceiling50/100Independent sourcesnot recordedPublished score50/100Scored at the ceiling for a unclassified source source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 28, 2026↗ source

The CDC has recommended the use of a lab-made antibody, nirsevimab, as a primary option to protect newborns from severe RSV. This single-dose injection is approved for infants younger than 8 months entering their first RSV season. The agency also endorsed a maternal vaccine strategy, creating two distinct immunization pathways to guard infants against the respiratory virus.

We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.